📊 BVS Key Takeaways
Is Bioventus Inc. (BVS) a Good Investment?
Bioventus demonstrates solid operational fundamentals with strong profitability (68.3% gross margin) and healthy free cash flow generation ($72.1M), but faces headwinds from flat revenue growth (-0.9% YoY) and declining net income (-16.7% YoY) despite EPS improvement. The company maintains adequate liquidity (1.70x current ratio) but carries significant leverage (1.52x debt/equity) that warrants monitoring.
Bioventus shows a fundamentally mixed profile: solid gross margins, positive operating leverage, and strong free cash flow generation support the business, but revenue is slightly declining and net income remains relatively thin versus sales. Financial health is adequate with acceptable liquidity, yet leverage is still meaningful, so the company looks operationally stable rather than clearly high-quality or high-growth.
Why Buy Bioventus Inc. Stock? BVS Key Strengths
- Exceptional gross margin of 68.3% indicates strong pricing power and operational efficiency in medical device manufacturing
- Robust free cash flow of $72.1M (12.7% FCF margin) with minimal capital intensity provides flexibility for debt reduction or shareholder returns
- Solid liquidity position with 1.70x current ratio and $51.2M cash balance supports operational resilience
- High gross margin of 68.3% indicates strong product economics and pricing power
- Free cash flow of $72.11M and a 12.7% FCF margin show good cash conversion
- Positive operating income and double-digit ROE suggest the business is profitable on a normalized basis
BVS Stock Risks: Bioventus Inc. Investment Risks
- Revenue stagnation at -0.9% YoY growth suggests market saturation, competitive pressure, or execution challenges in core business
- Net income declined 16.7% YoY despite flat revenues, indicating margin compression and rising operational costs or non-operating expenses
- Elevated debt-to-equity ratio of 1.52x with $279.0M long-term debt creates financial leverage risk and limits strategic flexibility
- Revenue declined 0.9% year over year, pointing to weak top-line momentum
- Net margin of 4.0% is modest, leaving limited room for execution missteps or cost pressure
- Debt-to-equity of 1.52x and long-term debt of $278.95M keep leverage risk elevated
Key Metrics to Watch
- Revenue growth trajectory - need to see return to positive growth to validate business model sustainability
- Operating margin trends - monitor if cost structure can stabilize at 9.5% level or if further pressure is coming
- Debt reduction pace - track whether $72.1M annual FCF is being allocated to deleverage or if leverage ratios worsen
- Revenue growth and operating margin trend
- Free cash flow generation relative to debt reduction
Bioventus Inc. (BVS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Bioventus Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BVS Profit Margin, ROE & Profitability Analysis
BVS vs Healthcare Sector: How Bioventus Inc. Compares
How Bioventus Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bioventus Inc. Stock Overvalued? BVS Valuation Analysis 2026
Based on fundamental analysis, Bioventus Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bioventus Inc. Balance Sheet: BVS Debt, Cash & Liquidity
BVS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bioventus Inc.'s revenue has grown significantly by 33% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.49 indicates the company is currently unprofitable.
BVS Revenue Growth, EPS Growth & YoY Performance
BVS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $138.7M | $3.2M | $0.05 |
| Q2 2025 | $147.7M | $4.8M | $0.07 |
| Q1 2025 | $123.9M | -$2.6M | $-0.04 |
| Q3 2024 | $120.8M | -$4.8M | $-0.07 |
| Q2 2024 | $137.1M | -$3.7M | $-0.06 |
| Q1 2024 | $119.1M | -$4.6M | $-0.07 |
| Q3 2023 | $120.8M | -$7.3M | $-0.12 |
| Q2 2023 | $137.1M | -$3.7M | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bioventus Inc. Dividends, Buybacks & Capital Allocation
BVS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bioventus Inc. (CIK: 0001665988)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 14, 2026 | 4 | xslF345X06/wk-form4_1776205136.xml | View → |
| Apr 14, 2026 | 4 | xslF345X06/wk-form4_1776205107.xml | View → |
| Apr 14, 2026 | 4 | xslF345X06/wk-form4_1776205072.xml | View → |
| Mar 24, 2026 | 4 | xslF345X06/wk-form4_1774385959.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773781416.xml | View → |
❓ Frequently Asked Questions about BVS
What is the AI rating for BVS?
Bioventus Inc. (BVS) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BVS's key strengths?
Claude: Exceptional gross margin of 68.3% indicates strong pricing power and operational efficiency in medical device manufacturing. Robust free cash flow of $72.1M (12.7% FCF margin) with minimal capital intensity provides flexibility for debt reduction or shareholder returns. ChatGPT: High gross margin of 68.3% indicates strong product economics and pricing power. Free cash flow of $72.11M and a 12.7% FCF margin show good cash conversion.
What are the risks of investing in BVS?
Claude: Revenue stagnation at -0.9% YoY growth suggests market saturation, competitive pressure, or execution challenges in core business. Net income declined 16.7% YoY despite flat revenues, indicating margin compression and rising operational costs or non-operating expenses. ChatGPT: Revenue declined 0.9% year over year, pointing to weak top-line momentum. Net margin of 4.0% is modest, leaving limited room for execution missteps or cost pressure.
What is BVS's revenue and growth?
Bioventus Inc. reported revenue of $568.1M.
Does BVS pay dividends?
Bioventus Inc. does not currently pay dividends.
Where can I find BVS SEC filings?
Official SEC filings for Bioventus Inc. (CIK: 0001665988) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BVS's EPS?
Bioventus Inc. has a diluted EPS of $0.33.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BVS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bioventus Inc. has a HOLD rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BVS stock overvalued or undervalued?
Valuation metrics for BVS: ROE of 12.3% (sector avg: 15%), net margin of 4.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BVS stock in 2026?
Our dual AI analysis gives Bioventus Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BVS's free cash flow?
Bioventus Inc.'s operating cash flow is $74.7M, with capital expenditures of $2.6M. FCF margin is 12.7%.
How does BVS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 4.0% (avg: 12%), ROE 12.3% (avg: 15%), current ratio 1.70 (avg: 2).
Is Bioventus Inc. carrying too much debt?
BVS has a debt-to-equity ratio of 1.52x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.70 suggests adequate short-term liquidity.